Migraine Trial, Recruiting NCT06459648 Sponsor: Fundación de Investigación Biomédica - Hospital Universitario de La Princesa Condition: Migraine
Back to Migraine

Migraine Trial, Recruiting

NCT06459648
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 65 years.
  • People of Caucasian ethnicity.
  • People who have been diagnosed by a headache specialist neurologist with either high-frequency episodic migraine (more than 8 migraine days per month) or chronic migraine, based on recognised international headache diagnostic guidelines.
  • People who have had a history of migraine for at least one year.
  • People whose preventive migraine treatment has remained unchanged in the month before starting the study, and who have not received botulinum toxin injections in that same month.
  • People who are able to clearly describe their symptoms and headache characteristics.
  • People who are willing to provide written informed consent to participate.

Who may not be able to join:

  • People who have another type of headache that is not migraine, except for headaches caused by overuse of pain relief medication.
  • People who show signs of a neurological problem on examination (confirm with trial site).
  • People who are pregnant or breastfeeding.
  • People who have a cognitive impairment or other condition that could prevent them from completing the study properly.
  • People who need to change their preventive migraine treatment within the first 6 months after starting the study medication.
  • People who experience a serious side effect that requires the study medication to be stopped or changed.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ana Beatriz Gago Veiga, Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

Phone: +34 915202416

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Registry
ClinicalTrials.gov
Start date
26 April 2023
Est. completion
1 July 2026

Where this trial is recruiting

🇪🇸 Spain

Primary endpoints

Biomarkers of positive initial response to monoclonal antibodies

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov